Heparanase Mechanisms in Brain-metastatic Breast Cancer
脑转移性乳腺癌中的乙酰肝素酶机制
基本信息
- 批准号:8450287
- 负责人:
- 金额:$ 27.95万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2011
- 资助国家:美国
- 起止时间:2011-07-21 至 2016-04-30
- 项目状态:已结题
- 来源:
- 关键词:AffectAngiogenic FactorAutomobile DrivingBindingBiologicalBloodBrainBreast Cancer CellCancer PatientCell ProliferationCellsCleaved cellClinical DataCoupledDevelopmentDiseaseEGFR Gene AmplificationERBB2 geneEndoglycosidasesEnzymesEpidermal Growth FactorEpidermal Growth Factor ReceptorExtracellular MatrixFosteringGlycolsGoalsGrowthGrowth FactorHeparinHeparitin SulfateHomingIn VitroKnowledgeLaboratoriesLightMammalsMediatingMediator of activation proteinMetastatic Neoplasm to the BreastMetastatic malignant neoplasm to brainMicroRNAsModalityNeoplasm Circulating CellsNeoplasm MetastasisOutcomePathway interactionsPatientsPharmaceutical PreparationsPhenotypePhosphorylationPlayProbabilityProcessProteinsRegulationResistanceRoleSignal TransductionSiteStagingSurvival RateSystemTechnologyTestingTherapeuticTissuesTumor BiologyTyrosineWorkaldehyde dehydrogenase 1basebrain cellcancer cellcancer stem celldesigneffective therapyexperienceheparanasehost neoplasm interactionin vivo Modelinhibitor/antagonistkinase inhibitorlapatinibmalignant breast neoplasmneoplastic cellpre-clinicalpromoterresearch studyresponserhosmall moleculesuccesstargeted deliverytherapy developmenttumor growthtumor progressiontumorigenic
项目摘要
DESCRIPTION (provided by applicant): The long-term goal of my laboratory is to determine mechanisms of heparanase in brain metastasis and to target heparanase therapeutically for this devastating disease. Our work has implicated heparanase as a promoter of brain metastasis. In particular, we have demonstrated that HPSE is expressed in brain metastatic breast cancer (BMBC) cells and tissues, and functions as a downstream target of HER2/EGFR pathways affecting BMBC cell proliferation. Our objective is now to determine how heparanase regulates BMBC and to use this knowledge to develop new heparanase-based therapies. Underscoring the importance of targeting heparanase, we have made four key discoveries that shed new light on the relevance of this molecule towards the aggressive BMBC phenotype. First, we identified microRNA-1258 as a microRNA that inhibits heparanase and suppresses BMBC. Second, we found that heparanase modulates EGFR phosphorylation at sites which are not targets of lapatinib, a dual HER2/EGFR kinase inhibitor, suggesting heparanase roles in mechanisms of lapatinib resistance. Third, we discovered that HPSE regulates Rac and Rho, critical mediators of cytoskeletal dynamics which is a fundamental process in the interplay between tumor cells and the microenvironment. Fourth, by investigating circulating tumor cells (CTCs) from the blood of BMBC patients, we discovered the expression of heparanase in CTCs, and a significant correlation between its presence, EGFR gene amplification, and ALDH1, a known cancer stem cell marker. A logical next step is to formulate strategies to inhibit HPSE and suppress BMBC. This can be achieved by using miR-1258 as well as new HPSE inhibitors, e.g., non-anticoagulant, glycol-split heparins. One of them, SST0001, has emerged as a potent small-molecule inhibitor of heparanase and is available to us. Based on our discoveries, we hypothesize that heparanase expression and function regulates the cross-talk between BMBC and cells of the brain microenvironment, and initiates multiple effects that are critical for the development and progression of BMBC. By proposing much broader roles for heparanase, which involve enzymatic and non-enzymatic functions, the following aims are designed to identify new mechanisms for this molecule keenly involved in BMBC progression. Aim 1 will determine the mechanisms of heparanase regulation by miR-1258 in relation to BMBC suppression. Aim 2 will identify functions of heparanase inhibitors, SST0001 and miR-1258, and their ability to overcome lapatinib resistance in BMBC cells. Aim 3 will delineate the roles of heparanase during the initial steps of BMBC development, signaling, and in brain-homing CTC modalities. Our approaches will include in vitro and in vivo models, coupled with lentiviral delivery targeting HPSE with miR-1258, new HPSE inhibitors, and cutting-edge CTC technologies. These studies emphasize the strong translational component of our proposed work by providing pre-clinical data to introduce heparanase inhibitors in more effective therapies to treat brain metastasis, in particular brain metastatic breast cancer.
描述(由申请人提供):我实验室的长期目标是确定乙酰肝素酶在脑转移中的机制,并靶向乙酰肝素酶治疗这种毁灭性疾病。我们的工作表明乙酰肝素酶是脑转移的促进剂。特别是,我们已经证明HPSE在脑转移性乳腺癌(BMBC)细胞和组织中表达,并作为影响BMBC细胞增殖的HER 2/EGFR途径的下游靶点发挥作用。我们的目标是确定乙酰肝素酶如何调节BMBC,并利用这些知识开发新的基于乙酰肝素酶的疗法。为了强调靶向乙酰肝素酶的重要性,我们已经取得了四项关键发现,这些发现揭示了这种分子与侵袭性BMBC表型的相关性。首先,我们鉴定了microRNA-1258作为抑制乙酰肝素酶和抑制BMBC的microRNA。其次,我们发现乙酰肝素酶调节EGFR磷酸化的位点不是拉帕替尼(一种双重HER 2/EGFR激酶抑制剂)的靶点,这表明乙酰肝素酶在拉帕替尼耐药机制中的作用。第三,我们发现HPSE调节Rac和Rho,细胞骨架动力学的关键介质,这是肿瘤细胞和微环境之间相互作用的基本过程。第四,通过研究来自BMBC患者血液的循环肿瘤细胞(CTC),我们发现了CTC中乙酰肝素酶的表达,以及其存在、EGFR基因扩增和已知癌症干细胞标志物ALDH 1之间的显著相关性。合乎逻辑的下一步是制定抑制HPSE和抑制BMBC的策略。这可以通过使用miR-1258以及新的HPSE抑制剂来实现,例如,无抗凝剂,乙二醇裂解肝素。其中之一,SST 0001,已成为一个有效的小分子乙酰肝素酶抑制剂,并提供给我们。基于我们的发现,我们假设乙酰肝素酶的表达和功能调节BMBC和脑微环境细胞之间的串扰,并启动对BMBC的发展和进展至关重要的多种效应。通过提出涉及酶和非酶功能的乙酰肝素酶更广泛的作用,以下目的旨在确定这种分子强烈参与BMBC进展的新机制。目的1将确定miR-1258调节乙酰肝素酶与BMBC抑制相关的机制。目的2将鉴定乙酰肝素酶抑制剂SST 0001和miR-1258的功能,以及它们克服BMBC细胞中拉帕替尼耐药性的能力。目的3将描述乙酰肝素酶在BMBC发展、信号传导和脑归巢CTC模式的初始步骤中的作用。我们的方法将包括体外和体内模型,再加上慢病毒递送靶向HPSE与miR-1258,新的HPSE抑制剂,和尖端的CTC技术。这些研究通过提供临床前数据来强调我们所提出的工作的强有力的转化组成部分,以将乙酰肝素酶抑制剂引入更有效的治疗脑转移的疗法中,特别是脑转移性乳腺癌。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Dario Marchetti其他文献
Dario Marchetti的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Dario Marchetti', 18)}}的其他基金
Mechanisms of melanoma brain metastasis by CTCs isolated from patients' blood and CSF
从患者血液和脑脊液中分离的 CTC 促进黑色素瘤脑转移的机制
- 批准号:
10532778 - 财政年份:2017
- 资助金额:
$ 27.95万 - 项目类别:
Mechanisms of melanoma brain metastasis by CTCs isolated from patients' blood and CSF
从患者血液和脑脊液中分离的 CTC 促进黑色素瘤脑转移的机制
- 批准号:
9828544 - 财政年份:2017
- 资助金额:
$ 27.95万 - 项目类别:
Mechanisms of melanoma brain metastasis by CTCs isolated from patients' blood and CSF
从患者血液和脑脊液中分离的 CTC 促进黑色素瘤脑转移的机制
- 批准号:
10023783 - 财政年份:2017
- 资助金额:
$ 27.95万 - 项目类别:
Mechanisms of melanoma brain metastasis by CTCs isolated from patients' blood and CSF
从患者血液和脑脊液中分离的 CTC 促进黑色素瘤脑转移的机制
- 批准号:
10308434 - 财政年份:2017
- 资助金额:
$ 27.95万 - 项目类别:
Functional characterization of brain-colonizing breast cancer CTC subsets
脑定植乳腺癌 CTC 亚群的功能特征
- 批准号:
10249055 - 财政年份:2016
- 资助金额:
$ 27.95万 - 项目类别:
Functional characterization of brain-colonizing breast cancer CTC subsets
脑定植乳腺癌 CTC 亚群的功能特征
- 批准号:
9762005 - 财政年份:2016
- 资助金额:
$ 27.95万 - 项目类别:
Functional characterization of brain-colonizing breast cancer CTC subsets
脑定植乳腺癌 CTC 亚群的功能特征
- 批准号:
9333288 - 财政年份:2016
- 资助金额:
$ 27.95万 - 项目类别:
Functional characterization of brain-colonizing breast cancer CTC subsets
脑定植乳腺癌 CTC 亚群的功能特征
- 批准号:
9150512 - 财政年份:2016
- 资助金额:
$ 27.95万 - 项目类别:
Heparanase Mechanisms in Brain-metastatic Breast Cancer
脑转移性乳腺癌中的乙酰肝素酶机制
- 批准号:
8657911 - 财政年份:2011
- 资助金额:
$ 27.95万 - 项目类别:
Heparanase Mechanisms in Brain-metastatic Breast Cancer
脑转移性乳腺癌中的乙酰肝素酶机制
- 批准号:
8153413 - 财政年份:2011
- 资助金额:
$ 27.95万 - 项目类别:
相似海外基金
How angiogenic factor induces immunosuppressive cells to tumor microenvironment
血管生成因子如何诱导免疫抑制细胞进入肿瘤微环境
- 批准号:
22KJ0818 - 财政年份:2023
- 资助金额:
$ 27.95万 - 项目类别:
Grant-in-Aid for JSPS Fellows
Validation of Adenylosuccinate as a Novel Endogenous Pro-Angiogenic Factor in the Brain
腺苷琥珀酸作为大脑中新型内源性促血管生成因子的验证
- 批准号:
10711027 - 财政年份:2021
- 资助金额:
$ 27.95万 - 项目类别:
Validation of Adenylosuccinate as a Novel Endogenous Pro-Angiogenic Factor in the Brain
腺苷琥珀酸作为大脑中新型内源性促血管生成因子的验证
- 批准号:
10297199 - 财政年份:2021
- 资助金额:
$ 27.95万 - 项目类别:
Validation of Adenylosuccinate as a Novel Endogenous Pro-Angiogenic Factor in the Brain
腺苷琥珀酸作为大脑中新型内源性促血管生成因子的验证
- 批准号:
10625314 - 财政年份:2021
- 资助金额:
$ 27.95万 - 项目类别:
Validation of Adenylosuccinate as a Novel Endogenous Pro-Angiogenic Factor in the Brain
腺苷琥珀酸作为大脑中新型内源性促血管生成因子的验证
- 批准号:
10405070 - 财政年份:2021
- 资助金额:
$ 27.95万 - 项目类别:
Physiological role of anti-angiogenic factor thrombospondin in the regulation of endometrial function during early pregnancy in cattle
抗血管生成因子血小板反应蛋白在牛妊娠早期子宫内膜功能调节中的生理作用
- 批准号:
20K06385 - 财政年份:2020
- 资助金额:
$ 27.95万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Elucidation of lymphangiogenic regulatory mechanism of angiogenic factor CCN2 through tumor-associated macrophage
阐明血管生成因子CCN2通过肿瘤相关巨噬细胞的淋巴管生成调节机制
- 批准号:
17K11866 - 财政年份:2017
- 资助金额:
$ 27.95万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Elucidation of vascular stabilization mechanism by anti-angiogenic factor vasohibin-1
抗血管生成因子 vasohibin-1 阐明血管稳定机制
- 批准号:
15K20874 - 财政年份:2015
- 资助金额:
$ 27.95万 - 项目类别:
Grant-in-Aid for Young Scientists (B)
angiogenic therapy for cerebral infarction with anti^sense homology derived peptide targeting angiogenic factor
靶向血管生成因子的反义同源肽治疗脑梗死
- 批准号:
15K15523 - 财政年份:2015
- 资助金额:
$ 27.95万 - 项目类别:
Grant-in-Aid for Challenging Exploratory Research
The development of the anti-angiogenic factor VEGF-A165b quantification methods for cardiovascular disease.
心血管疾病抗血管生成因子 VEGF-A165b 定量方法的开发。
- 批准号:
26860367 - 财政年份:2014
- 资助金额:
$ 27.95万 - 项目类别:
Grant-in-Aid for Young Scientists (B)